Optimizing the diabetic formulary: beyond aspirin and insulin
Steven P. Marso, MD, FACC*,*
* Mid America Heart Institute, Saint Luke’s Hospital, Kansas City, Missouri, USA
View larger version (22K):
[in a new window]
|
Figure 1 The survival curves for the depicted disease states are shown. Data are derived from the National Center for Health Statistics. This figure was adapted with permission from reference 4.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 This bar graph depicts the lifetime costs associated with the successful implementation of two blood pressure goals. This model was derived using a 60-year-old diabetic hypertensive patient with no prior history of cardiovascular or end-stage renal disease. This figure was adapted with permission from reference 50. ESRD = end-stage renal disease; HF = heart failure; MI = myocardial infarction.
|
|
View larger version (18K):
[in a new window]
|
Figure 3 The Kaplan-Meier estimates for all-cause mortality for the diabetic patients enrolled in MICRO-HOPE are shown. Figure reproduced with permission from reference 57.
|
|
View larger version (25K):
[in a new window]
|
Figure 4 One-year Kaplan-Meier estimates of the invasive treatment arms for the patients with diabetes mellitus enrolled in Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) are shown. A = the rate of death or myocardial infarction (MI) within EPISTENT; B = the 1-year target vessel revascularization (TVR) rates. PTCA = percutaneous transluminal coronary angioplasty.
|
|
|
